BioPharma Dive May 13, 2024
As commercial momentum builds, coverage incentives for the Medicare market are expected to favor biosimilars in 2025.
When biosimilar copies of AbbVie’s top-selling drug Humira arrived in 2023, the impact was hard to see. Now, that’s beginning to change as a few lower-cost versions gain ground.
Those inroads could be amplified by the Inflation Reduction Act, which may help boost the impact of biosimilar medicines on branded drugs.
Researchers at Harvard University examined the likely impact of the IRA on biosimilar coverage in Medicare and, in a new study, predicted that in 2025 the law will shift coverage from brand-name biologics to cheaper versions. Their findings come as other reports indicate biosimilars are finding their footing in the commercial market.
...Today's Sponsors
Today's Sponsor